mRNA vaccines are unique in their ability to activate multiple arms of the immune system (B cells, CD4+ and CD8+ T cells), and preliminary (not yet published) data with the Moderna melanoma neoantigen vaccine appears promising in the Phase 2 study. Here, CD8A is linked to melanoma.